Patient Perspective of Opioid Pain-Control Use After Mohs Micrographic Surgery
1. A theoretical risk of opioid addiction following surgery may affect patients’ choice of pain medications and thus, it is...
Identifying Culprit Drugs in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis
1. Physicians are more likely to over-label patients as allergic to non-culprit drugs, in comparison to missing possible culprit drugs...
Adulthood Atopic Dermatitis Associated With Venous Thromboembolism
1. Adulthood atopic dermatitis (AD) was significantly associated with an increased risk of venous thromboembolism (VTE); however, the absolute risk...
Maternal Alopecia Aerata and the Risk of Various Offspring Comorbidities
1. Offspring of mothers with alopecia areata had a significantly higher risk of autoimmune, inflammatory, atopic, thyroid, ad psychiatric disorders....
Comparing plasmapheresis and immunoglobulin-first therapy for patients with Stevens-Johnson syndrome and toxic epidermal necrolysis who previously received ineffective systemic corticosteroid therapy
1. No significant difference in mortality rates between inpatients with Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) who received...
SMiLE Randomized Trial Supports Incorporating Mindfulness and Self-Compassion Training into the Treatment Plan for Adult Patients with Atopic Dermatitis
1. Online mindfulness and self-compassion training, in addition to usual dermatologic care, improved the quality of life, disease symptoms, and...
Phase 2 Randomized Trial Supports Roflumilast as a Potential Treatment for Seborrheic Dermatitis
1. Erythema, scaling, and itching caused by seborrheic dermatitis (SD) significantly decreased with roflumilast treatment. 2. Roflumilast treated for SD...
Phase 1 Randomized Trial Supports Lovastatin as a Potential Primary Treatment for Disseminated Superficial Actinic Porokeratosis
1. Disseminated superficial actinic porokeratosis (DSAP) was improved in both treatment groups (i.e., lovastatin-cholesterol and lovastatin alone) with no serious...
ECZTRA 6 Phase 3 Randomized Trial Supports Tralokinumab for Adolescent Moderate-to-Severe Atopic Dermatitis
1. Interleukin-13 targeted treatment with tralokinumab was effective and well-tolerated for adolescent moderate-to-severe atopic dermatitis. 2. No new safety signals...
Narrow margin excision of T1a melanoma not associated with recurrence or melanoma-specific mortality
1. Wide local excision of T1a melanoma near critical structures with narrow (5-mm) margins was not associated with worse outcomes....